Biosimilars are biological products approved by the U.S. Food and Drug Administration based on the Agency’s rigorous standards for safety, potency and purity. Pfizer believes biosimilars have the potential to save the U.S. billions of dollars in health care costs – providing a solution that could lower costs for both patients and American taxpayers, as well as help improve public health. The 2019 approvals of oncology biosimilarsRuxience™ (rituximab-pvvr),Trazimera™ (trastuzumab-qyyp) andZirabev™ (bevacizumab-bvzr) mark a positive step forward for Pfizer in its role to continue expanding access to biosimilars for patients around the world.
With more than 10 years of global in-market experience and eight approved biosimilar products, Pfizer is proud to be at the forefront of this vital health care segment.
.jpg)
Share this page
